Arc-1 review

The tirzepatide price needs one consistent selected order

The current tirzepatide product description starts at $149 per month, but Arc-1’s catalogue lists the treatment from $199.99. Semaglutide’s page states a $199.99 monthly start. The tirzepatide difference is material enough to settle before comparing the service with another confirmed monthly program. ^{[1] [2] [3]}

The tirzepatide description identifies a compounded mixture with glycine and B12. Confirm the prescribed ingredients, concentration, supplied volume, first payment and next charge together. A concentration is not the full supplied quantity, and neither headline establishes that the same bill applies across every selected treatment arrangement.

Compare confirmed payments and supplied terms with the complete GLP-1 cost planner.

For a different term-total and staged-cancellation agreement, compare our RxION care-and-refund review.

The review step comes before fulfillment

Arc-1’s process places checkout and intake before practitioner review, followed by prescription processing if approved. The product pages advertise a zero-dollar consultation and free delivery. A purchase request does not guarantee treatment, and the home page’s construction notice makes current pathway availability worth confirming before an existing care arrangement is moved. ^{[1] [2] [4]}

The support page directs treatment questions to Chat with Doctor within the relevant account order and states a one-business-day reply target. Refill management also runs through the account. This identifies a practical contact route; it does not prove an observed response time, unlimited appointments or inclusion of every test. ^[5]

For another current enrollment and price comparison, read our BloomMD access-and-price review.

Keep approval and shortage claims attached to the actual product

The semaglutide page mixes discussion of approved branded medicines with a shortage-based explanation for compounding. FDA has announced resolution of the semaglutide and tirzepatide injection shortages and describes continuing conditions for compounded prescriptions. An older shortage explanation is not sufficient assurance for the current order. ^{[3] [7]}

The supplied compounded preparation is not FDA-approved. A brand-name trial cannot establish an identical result for it, and glycine or B12 does not by itself prove greater tolerability or make a prescription exempt from compounding conditions. The prescriber and dispenser need to address the actual clinical reason and preparation; the storefront cannot settle that through ingredient resemblance. ^{[2] [7] [8]}

Keep the tested product and population explicit in the semaglutide-versus-tirzepatide research.

A satisfaction badge is not the whole exit agreement

The treatment pages display a thirty-day guarantee. The support page says prescriptions are generally not returnable, while the general policy requires prior return approval, unused original-condition goods and proof of purchase. Obtain the exact prescription’s eligibility rather than assuming an ordinary post-use refund. ^{[2] [5] [6]}

Approved refunds are described as taking six to eight weeks to the original payment method. Confirm any recurring selection, renewal-processing date and cancellation terms separately. Choose the service for a confirmed clinical relationship and complete price, rather than allowing the smaller conflicting headline or the guarantee badge to carry the decision. ^{[6] [9]}

Separate clinical care from prescription fulfillment with our clinic-versus-pharmacy-access comparison.

Understanding the cost

Semaglutide page starts at $199.99/month. Tirzepatide product text starts at $149/month while its catalogue listing starts at $199.99. Confirm the selected compounded preparation, supplied term, initial and renewal bill; no single tirzepatide price is resolved here.